CVS Health Corporation Supplemental Financial Information Preliminary and Unaudited. Fourth Quarter 2014 Earnings Release February 10, 2015

Size: px
Start display at page:

Download "CVS Health Corporation Supplemental Financial Information Preliminary and Unaudited. Fourth Quarter 2014 Earnings Release February 10, 2015"

Transcription

1 CVS Health Corporation Supplemental Financial Information Preliminary and Unaudited Earnings Release February 10, 2015 The information in this report includes non-gaap financial measures related to our company s performance, namely EBITDA and Adjusted EPS. In accordance with SEC regulations, the definitions of the non-gaap items mentioned, as well as the reconciliations to comparable GAAP measures, are available on the investor relations portion of our website at investors.cvshealth.com. Preliminary and Unaudited (Revised r2) 1 of 9 February 10, 2015

2 Supplemental Information: Consolidated Statement of Income (In millions, except per share amounts) (4) (1) 2013 (2) Change Net revenues $ 37,055.3 $ 32, % $ 139,367.2 $ 126, % Cost of revenues 30, , % 113, , % Gross profit 6, , % 25, , % gross margin 17.9% 19.3% (140) bps 18.2% 18.8% (56) bps Operating expenses 4, ,121.5 (4.6%) 16, ,745.9 (5.2%) as a % of net revenues 11.6% 12.6% 92 bps 11.9% 12.4% 53 bps Operating profit $ 2,320.9 $ 2, % $ 8,799.1 $ 8, % operating margin 6.3% 6.8% (49) bps 6.3% 6.3% (3) bps Interest expense, net (3.0%) % Loss on early extinguishment of debt and foreign currency losses NM NM Income before income tax provision 2, , % 7, , % Amortization (3.4%) (5.0%) Adjusted income before income tax provision 2, , % 8, , % Adjusted income tax provision (3) (6.2%) 3, ,120.1 (3.8%) effective tax rate 39.6% 39.2% (41) bps 39.5% 38.9% (60) bps Earnings allocated to participating securities Adjusted income from continuing operations 1, , % 4, , % as a % of net revenues 3.8% 4.1% (32) bps 3.5% 3.9% (32) bps Net income attributable to noncontrolling interest (0.3) - (0.9) - Adjusted income from cont ops attributable to CVS Health $ 1,392.7 $ 1, % $ 4,938.8 $ 4, % as a % of net revenues 3.8% 4.1% (32) bps 3.5% 3.9% (32) bps Weighted average diluted common shares outstanding 1, , % 1, , % Adjusted EPS from continuing operations $ 1.21 $ % $ 4.22 $ % Depreciation (8.0%) 1, ,375.8 (2.7%) Depreciation and amortization (6.8%) 1, ,869.6 (3.3%) EBITDA $ 2,809.6 $ 2, % $ 10,730.0 $ 9, % as a % of net revenues 7.6% 8.1% (56) bps 7.7% 7.8% (12) bps 1 Includes a $521 million loss on early extinguishment of debt (approximately $0.27 per diluted share) during the year ended. Excluding this item, Adjusted EPS for the year ended, was $ Includes a $72 million gain on a legal settlement (approximately $0.04 per diluted share) during the year ended Excluding this item, Adjusted EPS for the year ended 2013, was $ The adjusted income tax provision is computed using the effective income tax rate computed from the consolidated statement of income. 4 Totals may not foot due to rounding. Preliminary and Unaudited (Revised r2) 2 of 9 February 10, 2015

3 Supplemental Information: Consolidated Statement of Income (Excluding Non-recurring Charges and Gains) (In millions, except per share amounts) (4) (1) 2013 (2) Change Net revenues $ 37,055.3 $ 32, % $ 139,367.2 $ 126, % Cost of revenues 30, , % 113, , % Gross profit 6, , % 25, , % gross margin 17.9% 19.3% (140) bps 18.2% 18.8% (56) bps Operating expenses 4, ,121.5 (4.6%) 16, ,817.7 (4.7%) as a % of net revenues 11.6% 12.6% 92 bps 11.9% 12.5% 59 bps Operating profit $ 2,320.9 $ 2, % $ 8,799.1 $ 7, % operating margin 6.3% 6.8% (49) bps 6.3% 6.3% 3 bps Interest expense, net (3.0%) % Loss on early extinguishment of debt and foreign currency losses Income before income tax provision NM NM 2, , % 8, , % Amortization (3.4%) (5.0%) Adjusted income before income tax provision 2, , % 8, , % Adjusted income tax provision (3) (6.2%) 3, ,092.2 (11.4%) effective tax rate 39.6% 39.2% (41) bps 39.5% 38.9% (60) bps Earnings allocated to participating securities Adjusted income from continuing operations 1, , % 5, , % as a % of net revenues 3.8% 4.1% (32) bps 3.8% 3.8% (6) bps Net income attributable to noncontrolling interest (0.3) - (0.9) - Adjusted income from cont ops attributable to CVS Health $ 1,392.7 $ 1, % $ 5,253.7 $ 4, % as a % of net revenues 3.8% 4.1% (32) bps 3.8% 3.8% (6) bps Weighted average diluted common shares outstanding 1, , % 1, , % Adjusted EPS from continuing operations $ 1.21 $ % $ 4.49 $ % Depreciation (8.0%) 1, ,375.8 (2.7%) Depreciation and amortization (6.8%) 1, ,869.6 (3.3%) EBITDA $ 2,809.6 $ 2, % $ 10,730.0 $ 9, % as a % of net revenues 7.6% 8.1% (56) bps 7.7% 7.8% (6) bps 1 Excludes a $521 million loss on early extinguishment of debt (approximately $0.27 per diluted share) during the year ended. Including this item, Adjusted EPS for the year ended, was $ Excludes a $72 million gain on a legal settlement (approximately $0.04 per diluted share) during the year ended Including this item, Adjusted EPS for the year ended 2013, was $ The adjusted income tax provision is computed using the effective income tax rate computed from the consolidated statement of income. 4 Totals may not foot due to rounding. Preliminary and Unaudited (Revised r2) 3 of 9 February 10, 2015

4 Supplemental Information: Pharmacy Services Segment (In millions, except per share amounts) (3) 2013 (1) Change Net revenues $ 23,874.2 $ 19, % $ 88,439.8 $ 76, % Cost of revenues 22, , % 83, , % Gross profit 1, , % 4, , % gross margin 5.2% 6.2% (99) bps 5.4% 5.6% (17) bps Operating expenses (5.9%) 1, ,150.3 (9.2%) as a % of net revenues 1.4% 1.6% 21 bps 1.4% 1.5% 9 bps Operating profit $ $ % $ 3,514.1 $ 3, % operating margin 3.8% 4.6% (78) bps 4.0% 4.1% (8) bps Depreciation and amortization (13.6%) (12.5%) EBITDA $ 1,070.1 $ 1, % $ 4,143.9 $ 3, % as a % of net revenues 4.5% 5.3% (83) bps 4.7% 4.8% (10) bps Net revenues: Mail choice 8, , % 31, , % Pharmacy network 15, , % 57, , % Other % % Pharmacy claims processed: Total % % Mail choice % (1.1%) Pharmacy network % % Total adjusted claims (2) % 1, , % Generic dispensing rate: Total 82.1% 80.8% 127 bps 82.2% 80.5% 175 bps Mail choice 75.1% 73.2% 190 bps 74.6% 72.6% 201 bps Pharmacy network 82.7% 81.6% 117 bps 83.0% 81.3% 169 bps Mail choice penetration rate 21.3% 22.7% (145) bps 21.4% 22.6% (113) bps 1 Includes an $11 million gain on a legal settlement during the year ended Includes the adjustment to convert 90-day, non-specialty prescriptions to the equivalent of three 30-day prescriptions. This adjustment reflects the fact that these prescriptions include approximately three times the amount of product days supplied compared to a normal 30-day prescription. 3 Totals may not foot due to rounding. Preliminary and Unaudited (Revised r2) 4 of 9 February 10, 2015

5 Supplemental Information: Pharmacy Services Segment (Excluding Non-recurring Charges and Gains) (In millions, except per share amounts) (3) 2013 (1) Change Net revenues $ 23,874.2 $ 19, % $ 88,439.8 $ 76, % Cost of revenues 22, , % 83, , % Gross profit 1, , % 4, , % gross margin 5.2% 6.2% (99) bps 5.4% 5.6% (17) bps Operating expenses (5.9%) 1, ,161.8 (8.2%) as a % of net revenues 1.4% 1.6% 21 bps 1.4% 1.5% 10 bps Operating profit $ $ % $ 3,514.1 $ 3, % operating margin 3.8% 4.6% (78) bps 4.0% 4.0% (6) bps Depreciation and amortization (13.6%) (12.5%) EBITDA $ 1,070.1 $ 1, % $ 4,143.9 $ 3, % as a % of net revenues 4.5% 5.3% (83) bps 4.7% 4.8% (8) bps Net revenues: Mail choice 8, , % 31, , % Pharmacy network 15, , % 57, , % Other % % Pharmacy claims processed: Total % % Mail choice % (1.1%) Pharmacy network % % Total adjusted claims (2) % 1, , % Generic dispensing rate: Total 82.1% 80.8% 127 bps 82.2% 80.5% 175 bps Mail choice 75.1% 73.2% 190 bps 74.6% 72.6% 201 bps Pharmacy network 82.7% 81.6% 117 bps 83.0% 81.3% 169 bps Mail choice penetration rate 21.3% 22.7% (145) bps 21.4% 22.6% (113) bps 1 Excludes an $11 million gain on a legal settlement during the year ended Includes the adjustment to convert 90-day, non-specialty prescriptions to the equivalent of three 30-day prescriptions. This adjustment reflects the fact that these prescriptions include approximately three times the amount of product days supplied compared to a normal 30-day prescription. 3 Totals may not foot due to rounding. Preliminary and Unaudited (Revised r2) 5 of 9 February 10, 2015

6 Supplemental Information: Retail Pharmacy Segment (In millions, except per share amounts) (3) 2013 (1) Change Net revenues $ 17,698.0 $ 17, % $ 67,797.9 $ 65, % Cost of revenues 12, , % 46, , % Gross profit 5, , % 21, , % gross margin 31.4% 30.7% 67 bps 31.4% 30.6% 73 bps Operating expenses 3, ,612.3 (4.6%) 14, ,844.2 (4.8%) as a % of net revenues 21.3% 21.0% (34) bps 21.4% 21.1% (31) bps Operating profit $ 1,779.7 $ 1, % $ 6,761.9 $ 6, % operating margin 10.1% 9.7% 33 bps 10.0% 9.6% 42 bps Depreciation and amortization (3.8%) 1, , % EBITDA $ 2,082.8 $ 1, % $ 7,966.9 $ 7, % as a % of net revenues 11.8% 11.4% 35 bps 11.8% 11.4% 34 bps Net revenues increase (decrease): Total 2.9% 5.6% (264) bps 3.3% 3.1% 21 bps Pharmacy 5.5% 8.5% (302) bps 5.1% 4.1% 105 bps Front store (4.9%) (0.5%) (435) bps (2.5%) 1.0% (347) bps Same-store increase (decrease): Total sales 1.6% 4.0% (240) bps 2.1% 1.7% 40 bps Pharmacy sales 5.5% 6.8% (130) bps 4.8% 2.6% 220 bps Front store sales (7.2%) (1.9%) (530) bps (4.0%) (0.5%) (350) bps Total prescription volume 3.2% 0.8% 240 bps 2.0% 1.5% 50 bps Total adj. prescription volume* 5.3% 3.8% 150 bps 4.1% 4.4% (30) bps Generic dispensing rate 82.4% 81.0% 140 bps 83.1% 81.4% 163 bps Rx % of net revenues 71.2% 69.5% 168 bps 70.7% 69.5% 117 bps 3 rd party % of Rx revenues 98.7% 98.1% 60 bps 98.6% 97.9% 70 bps Retail prescriptions filled % % Adj. retail prescriptions filled (2) % % 1 Includes a $61 million gain on a legal settlement during the year ended Includes the adjustment to convert 90-day, non-specialty prescriptions to the equivalent of three 30-day prescriptions. This adjustment reflects the fact that these prescriptions include approximately three times the amount of product days supplied compared to a normal 30-day prescription. 3 Totals may not foot due to rounding. Preliminary and Unaudited (Revised r2) 6 of 9 February 10, 2015

7 Supplemental Information: Retail Pharmacy Segment (Excluding Non-recurring Charges and Gains) (In millions, except per share amounts) (3) 2013 (1) Change Net revenues $ 17,698.0 $ 17, % $ 67,797.9 $ 65, % Cost of revenues 12, , % 46, , % Gross profit 5, , % 21, , % gross margin 31.4% 30.7% 67 bps 31.4% 30.6% 73 bps Operating expenses 3, ,612.3 (4.6%) 14, ,904.6 (4.4%) as a % of net revenues 21.3% 21.0% (34) bps 21.4% 21.2% (22) bps Operating profit $ 1,779.7 $ 1, % $ 6,761.9 $ 6, % operating margin 10.1% 9.7% 33 bps 10.0% 9.5% 51 bps Depreciation and amortization (3.8%) 1, , % EBITDA $ 2,082.8 $ 1, % $ 7,966.9 $ 7, % as a % of net revenues 11.8% 11.4% 35 bps 11.8% 11.3% 44 bps Net revenues increase (decrease): Total 2.9% 5.6% (264) bps 3.3% 3.1% 21 bps Pharmacy 5.5% 8.5% (302) bps 5.1% 4.1% 105 bps Front store (4.9%) (0.5%) (435) bps (2.5%) 1.0% (347) bps Same-store increase (decrease): Total sales 1.6% 4.0% (240) bps 2.1% 1.7% 40 bps Pharmacy sales 5.5% 6.8% (130) bps 4.8% 2.6% 220 bps Front store sales (7.2%) (1.9%) (530) bps (4.0%) (0.5%) (350) bps Total prescription volume 3.2% 0.8% 240 bps 2.0% 1.5% 50 bps Total adj. prescription volume* 5.3% 3.8% 150 bps 4.1% 4.4% (30) bps Generic dispensing rate 82.4% 81.0% 140 bps 83.1% 81.4% 163 bps Rx % of net revenues 71.2% 69.5% 168 bps 70.7% 69.5% 117 bps 3 rd party % of Rx revenues 98.7% 98.1% 60 bps 98.6% 97.9% 70 bps Retail prescriptions filled % % Adj. retail prescriptions filled (2) % % 1 Excludes a $61 million gain on a legal settlement during the year ended Includes the adjustment to convert 90-day, non-specialty prescriptions to the equivalent of three 30-day prescriptions. This adjustment reflects the fact that these prescriptions include approximately three times the amount of product days supplied compared to a normal 30-day prescription. 3 Totals may not foot due to rounding. Preliminary and Unaudited (Revised r2) 7 of 9 February 10, 2015

8 Supplemental Information: Corporate Segment (In millions, except per share amounts) (1) Net revenues $ - $ - N/A $ - $ - N/A Cost of revenues - - N/A - - N/A Gross profit - - N/A - - N/A gross margin N/A N/A N/A N/A N/A N/A Operating expenses (3.5%) (6.0%) as a % of net revenues N/A N/A N/A N/A N/A N/A Operating profit $ (205.0) $ (198.0) (3.5%) $ (796.4) $ (751.3) (6.0%) operating margin N/A N/A N/A N/A N/A N/A Depreciation and amortization (1.8%) (3.7%) EBITDA $ (180.7) $ (174.3) (3.7%) $ (700.4) $ (658.7) (6.3%) as a % of net revenues N/A N/A N/A N/A N/A N/A 1 Totals may not foot due to rounding. Preliminary and Unaudited (Revised r2) 8 of 9 February 10, 2015

9 Supplemental Information: Eliminations (In millions, except per share amounts) (1) Net revenues $ (4,517.0) $ (3,977.1) (13.6%) $ (16,870.5) $ (15,065.4) (12.0%) Cost of revenues (4,354.4) (3,819.6) (14.0%) (16,190.1) (14,499.1) (11.7%) Gross profit (162.6) (157.5) (3.2%) (680.4) (566.3) (20.2%) gross margin 3.6% 4.0% (36) bps 4.0% 3.8% 27 bps Operating expenses - - N/A - - N/A as a % of net revenues N/A N/A N/A N/A N/A N/A Operating profit $ (162.6) $ (157.5) (3.2%) $ (680.4) $ (566.3) (20.2%) operating margin 3.6% 4.0% (36) bps 4.0% 3.8% 27 bps Depreciation and amortization - - N/A - - N/A EBITDA $ (162.6) $ (157.5) (3.2%) $ (680.4) $ (566.3) (20.2%) as a % of net revenues 3.6% 4.0% (36) bps 4.0% 3.8% 27 bps 1 Totals may not foot due to rounding. Preliminary and Unaudited (Revised r2) 9 of 9 February 10, 2015

Q2 FY19 Supplemental Earnings Slides. October 29, 2018

Q2 FY19 Supplemental Earnings Slides. October 29, 2018 Q2 FY19 Supplemental Earnings Slides October 29, 2018 Safe Harbor Statement Some of the matters discussed in this presentation contain forward-looking statements regarding the Company s future business

More information

Reconciliation of Non-GAAP Items Required by SEC Rules

Reconciliation of Non-GAAP Items Required by SEC Rules 2016 ACTUAL RESULTS CVS Health is providing non-gaap information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance

More information

Reconciliation of Non-GAAP Items Required by SEC Rules

Reconciliation of Non-GAAP Items Required by SEC Rules 2016 ACTUAL RESULTS CVS Health is providing non-gaap information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance

More information

Cash Interest. Adjusted EBITDA Reconciliations

Cash Interest. Adjusted EBITDA Reconciliations Non-GAAP Financial Measures Cash Interest Cash Interest is a supplemental non-gaap financial measure that is used by management and external users of the Company s financial statements, such as industry

More information

First Quarter 2018 Financial Results Echo Global Logistics, Inc. April 25, 2018

First Quarter 2018 Financial Results Echo Global Logistics, Inc. April 25, 2018 First Quarter 2018 Financial Results Echo Global Logistics, Inc. April 25, 2018 Forward-Looking Statements All statements made in this presentation, other than statements of historical fact, are or may

More information

Reconciliation of Non-GAAP Items

Reconciliation of Non-GAAP Items 2016 GUIDANCE CVS Health is providing non-gaap information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and

More information

International Paper Company. Reconciliation of Non-GAAP Financial Measures

International Paper Company. Reconciliation of Non-GAAP Financial Measures International Paper Company Reconciliation of Non-GAAP Financial Measures This presentation includes certain non-u.s. GAAP financial measures. The calculation of these measures, and a reconciliation to

More information

CVS Caremark Reports Results for First Quarter First Quarter Year-Over-Year Highlights:

CVS Caremark Reports Results for First Quarter First Quarter Year-Over-Year Highlights: CVS Caremark Reports Results for First Quarter 2009 First Quarter Year-Over-Year Highlights: Adjusted EPS from continuing operations of $0.55 [excluding amortization] GAAP diluted EPS from continuing operations

More information

Non-GAAP Information 5/3/2018

Non-GAAP Information 5/3/2018 5/3/2018 Use of Non-GAAP Financial Information: The Company believes that non-gaap performance measures, which management uses in evaluating the Company's business, may provide users of the Company's financial

More information

1 sur 10 03/02/ :56

1 sur 10 03/02/ :56 1 sur 10 03/02/2011 13:56 Print Page Close Window Press Release

More information

Reconciliations to GAAP and Share Information

Reconciliations to GAAP and Share Information 98 Reconciliations to GAAP and Share Information Reconciliation of Net Income to Adjusted EBITDA (1) 2016 Q1 Q2 Q3 Q4 Full Year (in millions, except per share data) Total Net Income $ 76.7 $ 81.2 $ 78.1

More information

International Paper Company. Reconciliation of Non-GAAP Financial Measures

International Paper Company. Reconciliation of Non-GAAP Financial Measures International Paper Company Reconciliation of Non-GAAP Financial Measures This presentation includes certain non-u.s. GAAP financial measures. The calculation of these measures, and a reconciliation to

More information

CVS CAREMARK REPORTS RECORD SECOND QUARTER REVENUES, OPERATING PROFIT, AND EARNINGS

CVS CAREMARK REPORTS RECORD SECOND QUARTER REVENUES, OPERATING PROFIT, AND EARNINGS Investor Contact: Nancy Christal Media Contact: Eileen Howard Dunn Senior Vice President Senior Vice President Investor Relations Corporate Communications & (914) 722-4704 Community Relations (401) 770-4561

More information

Reconciliation of Non-GAAP Financial Measures. Adjusted Operating Income Reconciliation

Reconciliation of Non-GAAP Financial Measures. Adjusted Operating Income Reconciliation Reconciliation of Non-GAAP Financial Measures Adjusted Operating Income Reconciliation Adjusted operating income is not a measure of financial performance under generally accepted accounting principles

More information

Bottomline Technologies Reconciliation to Non GAAP Measures Three Months Ended June 30, 2013

Bottomline Technologies Reconciliation to Non GAAP Measures Three Months Ended June 30, 2013 Reconciliation to Measures Three Months Ended June 30, 2013 Non Cash Amortization of Equity Based Integration Restructuring Interest GAAP Intangible Assets Compensation Related Expenses Expenses Expense

More information

October 24, Q Supplemental Information

October 24, Q Supplemental Information October 24, 2018 Q3 2018 Supplemental Information Non-GAAP Disclaimer The financial results disclosed in this presentation include certain measures calculated and presented in accordance with GAAP. In

More information

2013 Oldemark LLC. Third-Quarter 2014 Conference Call November 6, 2014

2013 Oldemark LLC. Third-Quarter 2014 Conference Call November 6, 2014 2013 Oldemark LLC Third-Quarter 2014 Conference Call November 6, 2014 DAVID POPLAR Vice President Investor Relations 2013 Oldemark LLC 2 Today s Agenda CEO Overview Financial Update Q&A Emil Brolick Todd

More information

Reconciliation of Non-GAAP Measures

Reconciliation of Non-GAAP Measures Earnings Before Interest, Taxes, Depreciation, Amortization and Acquisition & Integration Expenses Net income applicable to TRC Companies, Inc.'s common shareholders $ 3,998 $ 3,937 Interest expense 841

More information

July 24, Q Supplemental Information

July 24, Q Supplemental Information July 24, 2018 Q2 2018 Supplemental Information Non-GAAP Disclaimer The financial results disclosed in this presentation include certain measures calculated and presented in accordance with GAAP. In addition

More information

Third Quarter 2018 Financial Results Echo Global Logistics, Inc. October 24, 2018

Third Quarter 2018 Financial Results Echo Global Logistics, Inc. October 24, 2018 Third Quarter 2018 Financial Results Echo Global Logistics, Inc. October 24, 2018 Forward-Looking Statements All statements made in this presentation, other than statements of historical fact, are or may

More information

Sales $ 407,444 $ 396,064 $ 1,602,580 $ 1,515,608 Cost of sales (258,660) (242,460) (1,021,230) (952,221)

Sales $ 407,444 $ 396,064 $ 1,602,580 $ 1,515,608 Cost of sales (258,660) (242,460) (1,021,230) (952,221) CONSOLIDATED STATEMENTS OF INCOME (Unaudited) (Dollar amounts in thousands, except per share data) 2018 2017 2018 2017 Sales $ 407,444 $ 396,064 $ 1,602,580 $ 1,515,608 Cost of sales (258,660) (242,460)

More information

MYERS INDUSTRIES, INC. First Quarter 2018 Earnings Presentation

MYERS INDUSTRIES, INC. First Quarter 2018 Earnings Presentation MYERS INDUSTRIES, INC. First Quarter 2018 Earnings Presentation SAFE HARBOR STATEMENT & NON-GAAP MEASURES Statements in this presentation concerning the Company s goals, strategies and expectations for

More information

3 rd Quarter Fiscal 2019

3 rd Quarter Fiscal 2019 3 rd Quarter Fiscal 2019 SUPPLEMENTAL INFORMATION December 19, 2018 SAFE HARBOR STATEMENT Cautionary Statement Regarding Forward Looking Statements Statements in this presentation that are not historical,

More information

Q Supplemental Financial Information. August 2, 2018

Q Supplemental Financial Information. August 2, 2018 August 2, 2018 This presentation may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future

More information

DANA HOLDING CORPORATION Quarterly Financial Information and Reconciliations of Non-GAAP Financial Measures

DANA HOLDING CORPORATION Quarterly Financial Information and Reconciliations of Non-GAAP Financial Measures Quarterly Financial Information and Reconciliations of Non-GAAP Financial Measures Non-GAAP Financial Measures Adjusted EBITDA is a non-gaap financial measure which we have defined as earnings from continuing

More information

Reconciliation of Non-GAAP Measures

Reconciliation of Non-GAAP Measures Earnings Before Interest, Taxes, Depreciation, Amortization and Goodwill & Intangible Asset Impairment Q4-2015 Q4-2016 Net income applicable to TRC Companies, Inc.'s common shareholders $6.8 $5.9 Interest

More information

Investor Nancy Christal Media Carolyn Castel Contact: Senior Vice President Contact: Vice President (914) (401)

Investor Nancy Christal Media Carolyn Castel Contact: Senior Vice President Contact: Vice President (914) (401) Investor Nancy Christal Media Carolyn Castel Contact: Senior Vice President Contact: Vice President Investor Relations Corporate Communications (914) 722-4704 (401) 770-5717 FOR IMMEDIATE RELEASE CVS HEALTH

More information

DICK'S SPORTING GOODS, INC. GAAP to NON-GAAP RECONCILIATIONS (Dollars in thousands, except per share amounts) (unaudited)

DICK'S SPORTING GOODS, INC. GAAP to NON-GAAP RECONCILIATIONS (Dollars in thousands, except per share amounts) (unaudited) DICK'S SPORTING GOODS, INC. GAAP to NON-GAAP RECONCILIATIONS (Dollars in thousands, except per share amounts) (unaudited) 13 Weeks Ended January 28, 2017 Cost of goods sold Selling, general and administrative

More information

Investor Mike McGuire Media Carolyn Castel Contact: Senior Vice President Contact: Vice President (401) (401) FOR IMMEDIATE RELEASE

Investor Mike McGuire Media Carolyn Castel Contact: Senior Vice President Contact: Vice President (401) (401) FOR IMMEDIATE RELEASE Investor Mike McGuire Media Carolyn Castel Contact: Senior Vice President Contact: Vice President Investor Relations Corporate Communications (401) 770-4050 (401) 770-5717 FOR IMMEDIATE RELEASE CVS HEALTH

More information

MYERS INDUSTRIES, INC. Second Quarter 2018 Earnings Presentation

MYERS INDUSTRIES, INC. Second Quarter 2018 Earnings Presentation MYERS INDUSTRIES, INC. Second Quarter 2018 Earnings Presentation SAFE HARBOR STATEMENT & NON-GAAP MEASURES Statements in this presentation concerning the Company s goals, strategies and expectations for

More information

CMS ENERGY CORPORATION Reconciliation of Non-GAAP FFO to Average Debt Ratio (Unaudited)

CMS ENERGY CORPORATION Reconciliation of Non-GAAP FFO to Average Debt Ratio (Unaudited) GAAP Reconciliation Reconciliation of Non-GAAP FFO to Average Debt Ratio FUNDS FROM OPERATIONS 12/31/17 Year Ended In Millions Net Cash Provided by Operating Activities $ 1,705 Reconciling item: Securitization

More information

August 5 th, Calendar Year Second Quarter Conference Call

August 5 th, Calendar Year Second Quarter Conference Call August 5 th, 2015 Calendar Year Second Quarter Conference Call 0 Forward - Looking Statements Note: Certain statements in this presentation are forward-looking statements." These statements relate to future

More information

FORWARD LOOKING STATEMENTS

FORWARD LOOKING STATEMENTS SECOND QUARTER 2018 FORWARD LOOKING STATEMENTS Forward-looking statements in this presentation, including statements regarding demand, product development and capital expenditure plans and timing of those

More information

Research, development & engineering

Research, development & engineering Revenues Sales 5,214 1,107 1,205 1,132 1,230 4,674 1,003 1,126 1,057 1,133 4,319 936 1,010 981 2,927 Services, maintenance and rentals 7,078 1,610 1,634 1,569 1,632 6,445 1,529 1,585 1,489 1,524 6,127

More information

First Quarter 2018 Earnings Call. May 10, 2018

First Quarter 2018 Earnings Call. May 10, 2018 First Quarter 2018 Earnings Call May 10, 2018 Forward-Looking Statements This presentation includes certain statements relating to future events and our intentions, beliefs, expectations, and predictions

More information

Edwards Lifesciences Corporation Unaudited Consolidated Statements of Operations

Edwards Lifesciences Corporation Unaudited Consolidated Statements of Operations Unaudited Consolidated Statements of Operations Three Months Ended March 31, (in millions, except per share data) 2003 2002 Net sales $212.5 $162.3 Cost of goods sold 89.1 69.1 Gross profit 123.4 93.2

More information

NEW REVENUE ACCOUNTING STANDARD (ASC 606) February 7, 2018

NEW REVENUE ACCOUNTING STANDARD (ASC 606) February 7, 2018 NEW REVENUE ACCOUNTING STANDARD February 7, 2018 DISCLAIMERS Forward-Looking Statements Statements in this document that are not statements of historical fact are forward-looking statements within the

More information

Brooks Automation, Inc. 4 th Quarter Fiscal 2013 Financial Results Conference Call

Brooks Automation, Inc. 4 th Quarter Fiscal 2013 Financial Results Conference Call Brooks Automation, Inc. 4 th Quarter Fiscal 2013 Financial Results Conference Call November 14, 2013 Safe Harbor Statement Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act

More information

Investor Mike McGuire Media Carolyn Castel Contact: Senior Vice President Contact: Vice President (401) (401) FOR IMMEDIATE RELEASE

Investor Mike McGuire Media Carolyn Castel Contact: Senior Vice President Contact: Vice President (401) (401) FOR IMMEDIATE RELEASE Investor Mike McGuire Media Carolyn Castel Contact: Senior Vice President Contact: Vice President Investor Relations Corporate Communications (401) 770-4050 (401) 770-5717 FOR IMMEDIATE RELEASE CVS HEALTH

More information

(24.6) (23.6) Other income (expense), net 3.1 (0.8) Consolidated income before income taxes Provision for income taxes

(24.6) (23.6) Other income (expense), net 3.1 (0.8) Consolidated income before income taxes Provision for income taxes EQUIFAX CONSOLIDATED STATEMENTS OF INCOME (In millions, except per share amounts) Three Months Ended June 30, 2017 2016 (Unaudited) Operating revenue $ 856.7 $ 811.3 Operating expenses: Cost of services

More information

Appendix. Non-GAAP Adjustments

Appendix. Non-GAAP Adjustments Appendix Non-GAAP Adjustments Reconciliation of Reported (GAAP) to Adjusted (non GAAP) Financial Measures (Dollar amounts in millions, except per share data) 00 006 007 008 009 3 00 0 4 0 03 6 04 7 0 8

More information

(24.2) (20.1) Other income (expense), net 3.1 (2.1 ) Consolidated income from operations before income taxes Provision for income taxes

(24.2) (20.1) Other income (expense), net 3.1 (2.1 ) Consolidated income from operations before income taxes Provision for income taxes EQUIFAX CONSOLIDATED STATEMENTS OF INCOME (In millions, except per share amounts) Three Months Ended March 31, 2017 2016 (Unaudited) Operating revenue $ 832.2 $ 728.3 Operating expenses: Cost of services

More information

Analog Devices, Fourth Quarter, Fiscal Schedule A Revenue and Earnings Summary (Unaudited) (In thousands, except per-share amounts) Nov.

Analog Devices, Fourth Quarter, Fiscal Schedule A Revenue and Earnings Summary (Unaudited) (In thousands, except per-share amounts) Nov. Analog Devices, Fourth Quarter, Fiscal Schedule A Revenue and Earnings Summary (Unaudited) (In thousands, except per-share amounts) Revenue $ 814,247 $ 727,752 $ 678,133 $ 2,864,773 $ 2,633,689 Year-to-year

More information

MYERS INDUSTRIES, INC. Third Quarter 2018 Earnings Presentation

MYERS INDUSTRIES, INC. Third Quarter 2018 Earnings Presentation MYERS INDUSTRIES, INC. Third Quarter 2018 Earnings Presentation SAFE HARBOR STATEMENT & NON-GAAP MEASURES Statements in this presentation include forward-looking statements within the meaning of the Private

More information

CMS ENERGY CORPORATION Earnings Per Share By Year GAAP Reconciliation (Unaudited)

CMS ENERGY CORPORATION Earnings Per Share By Year GAAP Reconciliation (Unaudited) GAAP Reconciliation Earnings Per Share By Year GAAP Reconciliation 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Reported earnings (loss) per share - GAAP ($0.30) $0.64 ($0.44)

More information

rd Quarter Results

rd Quarter Results 2017 3 rd Quarter Results Non-GAAP Financial Measures Non-GAAP Financial Measures This presentation includes certain non-gaap financial measures, including constant currency sales, Adjusted EBITDA, constant

More information

KKR STATEMENTS OF OPERATIONS SUPPLEMENTAL PRIOR PERIOD SEGMENT INFORMATION QUARTER ENDED MARCH 31, 2014 (Amounts in thousands)

KKR STATEMENTS OF OPERATIONS SUPPLEMENTAL PRIOR PERIOD SEGMENT INFORMATION QUARTER ENDED MARCH 31, 2014 (Amounts in thousands) QUARTER ENDED MARCH 31, 2014 Management Fees $ 123,039 $ 72,354 $ - $ 195,393 Monitoring Fees 36,363 - - 36,363 Transaction Fees 93,020 6,022 64,474 163,516 Fee Credits (80,338) (4,330) - (84,668) Total

More information

First Quarter 2018 Financial Review and Analysis (preliminary, unaudited)

First Quarter 2018 Financial Review and Analysis (preliminary, unaudited) First Quarter 2018 Financial Review and Analysis (preliminary, unaudited) Supplemental Presentation Materials Unless otherwise indicated, comparisons are to the same period in the prior year. 1 First Quarter

More information

2

2 News Release 1 2 3 4 5 6 Ashland Global Holdings Inc. and Consolidated Subsidiaries Table 1 STATEMENTS OF CONSOLIDATED INCOME (LOSS) (In millions except per share data - preliminary and unaudited) Three

More information

Earnings Conference Call

Earnings Conference Call First Quarter 2015 Earnings Conference Call Larry Merlo President & Chief Executive Officer Dave Denton Executive Vice President & Chief Financial Officer May 1, 2015 Forward-looking Statements During

More information

MERITOR, INC. CONSOLIDATED STATEMENT OF OPERATIONS (Unaudited) (In millions, except per share amounts)

MERITOR, INC. CONSOLIDATED STATEMENT OF OPERATIONS (Unaudited) (In millions, except per share amounts) CONSOLIDATED STATEMENT OF OPERATIONS (Unaudited) (In millions, except per share amounts) 2014 2013 2014 2013 Sales $ 933 $ 902 $ 3,766 $ 3,672 Cost of sales (793 ) (793 ) (3,279 ) (3,277 ) GROSS MARGIN

More information

Earnings. Larry Merlo. President & Chief Executive Officer. Executive Vice President & Chief Financial Officer. November 4, 2014

Earnings. Larry Merlo. President & Chief Executive Officer. Executive Vice President & Chief Financial Officer. November 4, 2014 Third dquate Quarter Earnings Conference Call Larry Merlo President & Chief Executive Officer Dave Denton Executive Vice President & Chief Financial Officer November 4, 2014 Forward-looking Statements

More information

DYCOM INDUSTRIES, INC. Trend Schedule August 30, 2017

DYCOM INDUSTRIES, INC. Trend Schedule August 30, 2017 DYCOM INDUSTRIES, INC. Trend Schedule August 30, 2017 The trend schedules are unaudited and include certain financial measures that are considered Non GAAP financial measures, as defined by Regulation

More information

Forecasted 2008 Total Ongoing Segment and Other EBIT and EBITDA

Forecasted 2008 Total Ongoing Segment and Other EBIT and EBITDA Non-GAAP Reconciliation for SEC Regulation G Employee Incentive Targets 2008 presentation include a discussion of the 2007 and 2008 ongoing fully diluted earnings per share ( EPS ) employee incentive targets

More information

ON SEMICONDUCTOR CORPORATION AND SUBSIDIARIES UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS (in millions, except per share data)

ON SEMICONDUCTOR CORPORATION AND SUBSIDIARIES UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS (in millions, except per share data) ON SEMICONDUCTOR CORPORATION AND SUBSIDIARIES UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS (in millions, except per share data) Quarter Ended Six Months Ended March 31, July 1, July 1, Revenue $ 1,338.0

More information

Albemarle Corporation Second Quarter 2018 Earnings and Non-GAAP Reconciliations Conference Call/Webcast Wednesday, August 8 th, :00am ET

Albemarle Corporation Second Quarter 2018 Earnings and Non-GAAP Reconciliations Conference Call/Webcast Wednesday, August 8 th, :00am ET Albemarle Corporation Second Quarter 2018 Earnings and Non-GAAP Reconciliations Conference Call/Webcast Wednesday, August 8 th, 2018 9:00am ET Forward-Looking Statements Some of the information presented

More information

December 31, 2017 January 1, 2017

December 31, 2017 January 1, 2017 CYPRESS SEMICONDUCTOR CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) (Unaudited) December 31, January 1, ASSETS Cash, cash equivalents and short-term investments $ 151,596 $ 120,172 Accounts

More information

2

2 1 2 3 4 5 6 Ashland Global Holdings Inc. and Consolidated Subsidiaries Table 1 STATEMENTS OF CONSOLIDATED INCOME (LOSS) (In millions except per share data - preliminary and unaudited) Three months ended

More information

Forward-looking Statement Disclosure

Forward-looking Statement Disclosure Third Quarter 2017 Earnings Call Presentation Valmont Industries. Inc. 2017 Investor Day Forward-looking Statement Disclosure These slides contain (and the accompanying oral discussion will contain) forwardlooking

More information

Second Quarter 2018 GAAP to Non-GAAP Reconciliations. July 25, 2018

Second Quarter 2018 GAAP to Non-GAAP Reconciliations. July 25, 2018 Second Quarter 2018 GAAP to Non-GAAP Reconciliations July 25, 2018 1 Supplemental Information GAAP to Non-GAAP Reconciliations ($ in thouss, except share per share amounts) (unaudited) 2018 2017 2018 2017

More information

Second Quarter 2018 Financial Review and Analysis (preliminary, unaudited)

Second Quarter 2018 Financial Review and Analysis (preliminary, unaudited) Second Quarter 2018 Financial Review and Analysis (preliminary, unaudited) Supplemental Presentation Materials Unless otherwise indicated, comparisons are to the same period in the prior year. 1 Second

More information

GAAP/Non-GAAP Reconciliation and Other Management Metrics. 3rd Quarter 2017

GAAP/Non-GAAP Reconciliation and Other Management Metrics. 3rd Quarter 2017 GAAP/Non-GAAP Reconciliation and Other Management Metrics 3rd Quarter 2017 Use of Non-GAAP Financial Information Use of Non-GAAP Financial Information The Company occasionally utilizes financial measures

More information

Target Reports Second Quarter 2016 Earnings Better-than-expected profitability; comparable sales in line with guidance

Target Reports Second Quarter 2016 Earnings Better-than-expected profitability; comparable sales in line with guidance FOR IMMEDIATE RELEASE Contacts: John Hulbert, Investors, (612) 761-6627 Erin Conroy, Media, (612) 761-5928 Target Media Hotline, (612) 696-3400 Target Reports Second Quarter Earnings Better-than-expected

More information

April 26, Q Supplemental Information

April 26, Q Supplemental Information April 26, 2018 Q1 2018 Supplemental Information Non-GAAP Disclaimer The financial results disclosed in this presentation include certain measures calculated and presented in accordance with GAAP. In addition

More information

Investor Mike McGuire Media Carolyn Castel Contact: Senior Vice President Contact: Vice President (401) (401) FOR IMMEDIATE RELEASE

Investor Mike McGuire Media Carolyn Castel Contact: Senior Vice President Contact: Vice President (401) (401) FOR IMMEDIATE RELEASE Investor Mike McGuire Media Carolyn Castel Contact: Senior Vice President Contact: Vice President Investor Relations Corporate Communications (401) 770-4050 (401) 770-5717 FOR IMMEDIATE RELEASE CVS HEALTH

More information

ACXIOM Q2 FY18 Conference Call. November 1, 2017

ACXIOM Q2 FY18 Conference Call. November 1, 2017 ACXIOM Q2 FY8 Conference Call November, 207 SAFE HARBOR STATEMENT Some of the matters discussed in this presentation contain forward-looking statements regarding the company s future business prospects

More information

ON SEMICONDUCTOR CORPORATION AND SUBSIDIARIES UNAUDITED CONSOLIDATED STATEMENT OF OPERATIONS (in millions, except per share data)

ON SEMICONDUCTOR CORPORATION AND SUBSIDIARIES UNAUDITED CONSOLIDATED STATEMENT OF OPERATIONS (in millions, except per share data) ON SEMICONDUCTOR CORPORATION AND SUBSIDIARIES UNAUDITED CONSOLIDATED STATEMENT OF OPERATIONS (in millions, except per share data) Quarter Ended October 2, Year Ended Revenues $ 840.3 $ 904.2 $ 864.2 $

More information

Q and FY 2016 earnings summary. February 28, 2017 Extended Stay America, Inc. ESH Hospitality, Inc.

Q and FY 2016 earnings summary. February 28, 2017 Extended Stay America, Inc. ESH Hospitality, Inc. Q4 2016 and FY 2016 earnings summary February 28, 2017 Extended Stay America, Inc. ESH Hospitality, Inc. important disclosure information This presentation contains forward-looking statements within the

More information

Investor Mike McGuire Media Carolyn Castel Contact: Senior Vice President Contact: Vice President (401) (401) FOR IMMEDIATE RELEASE

Investor Mike McGuire Media Carolyn Castel Contact: Senior Vice President Contact: Vice President (401) (401) FOR IMMEDIATE RELEASE Investor Mike McGuire Media Carolyn Castel Contact: Senior Vice President Contact: Vice President Investor Relations Corporate Communications (401) 770-4050 (401) 770-5717 FOR IMMEDIATE RELEASE CVS HEALTH

More information

Investor Mike McGuire Media Carolyn Castel Contact: Senior Vice President Contact: Vice President (401) (401) FOR IMMEDIATE RELEASE

Investor Mike McGuire Media Carolyn Castel Contact: Senior Vice President Contact: Vice President (401) (401) FOR IMMEDIATE RELEASE Investor Mike McGuire Media Carolyn Castel Contact: Senior Vice President Contact: Vice President Investor Relations Corporate Communications (401) 770-4050 (401) 770-5717 FOR IMMEDIATE RELEASE CVS HEALTH

More information

Net sales $ 1,874 $ 1,759 $ 7,644 $ 7,357 Cost of sales 1,258 1,186 5,033 4,901 Gross profit ,611 2,456

Net sales $ 1,874 $ 1,759 $ 7,644 $ 7,357 Cost of sales 1,258 1,186 5,033 4,901 Gross profit ,611 2,456 Condensed Consolidated Statements of Operations - Unaudited For the Three Months and 2017 and 2016 (in millions, except per common share data) 2017 2016 2017 2016 Net sales $ 1,874 $ 1,759 $ 7,644 $ 7,357

More information

Coherent, Inc. Consolidated Statement of Operations - GAAP

Coherent, Inc. Consolidated Statement of Operations - GAAP Consolidated Statement of Operations - GAAP (In thousands except percentages and per share data, unaudited) March 31, December 30, September 30, July 1, April 1, December 31, October 1, July 2, April 2,

More information

4Q 2016 Earnings Webcast. Solutions that Protect and Promote the World s Great Brands

4Q 2016 Earnings Webcast. Solutions that Protect and Promote the World s Great Brands 4Q 2016 Earnings Webcast Solutions that Protect and Promote the World s Great Brands Net Sales (US$ millions) $500 $1,900 $1,835.2 $450 $1,800 $1,738.6 $1,741.6 $1,700 $400 $379.8 $373.8 $379.8 $373.8

More information

DICK'S SPORTING GOODS, INC. GAAP to NON-GAAP RECONCILIATIONS (Dollars in thousands, except per share amounts) (unaudited)

DICK'S SPORTING GOODS, INC. GAAP to NON-GAAP RECONCILIATIONS (Dollars in thousands, except per share amounts) (unaudited) 13 Weeks Ended October 28, 2017 Other income Income before income taxes Net income GAAP Basis $ (10,768) $ 57,930 $ 36,913 $ 0.35 % of Net Sales (0.55)% 2.98% 1.90% Sales tax refund 8,104 (8,104) (5,024)

More information

February 7, Q4 & Full Year 2017 Supplemental Information

February 7, Q4 & Full Year 2017 Supplemental Information February 7, 2018 Q4 & Full Year Supplemental Information Non-GAAP Disclaimer The financial results disclosed in this presentation include certain measures calculated and presented in accordance with GAAP.

More information

Fourth Quarter and Full Year 2018 Financial Review and Analysis

Fourth Quarter and Full Year 2018 Financial Review and Analysis Fourth Quarter and Full Year 2018 Financial Review and Analysis (preliminary, unaudited) Supplemental Presentation Materials Unless otherwise indicated, comparisons are to the same periods in the prior

More information

FIRST QUARTER 2018 EARNINGS CONFERENCE CALL MAY 9, 2018

FIRST QUARTER 2018 EARNINGS CONFERENCE CALL MAY 9, 2018 FIRST QUARTER 2018 EARNINGS CONFERENCE CALL MAY 9, 2018 Forward-Looking Statements and Non-GAAP Financial Measures Forward-Looking Statements This webcast and presentation contain statements that are forward-looking

More information

Reconciliation of Non-GAAP Metrics and Definitions

Reconciliation of Non-GAAP Metrics and Definitions Reconciliation of Non-GAAP Metrics and Definitions Definitions of Non-GAAP Financial Measures Adjusted EBITDA GAAP net income excluding the following items: interest income; income taxes; depreciation

More information

ON SEMICONDUCTOR CORPORATION AND SUBSIDIARIES UNAUDITED CONSOLIDATED STATEMENT OF OPERATIONS (in millions, except per share data)

ON SEMICONDUCTOR CORPORATION AND SUBSIDIARIES UNAUDITED CONSOLIDATED STATEMENT OF OPERATIONS (in millions, except per share data) UNAUDITED CONSOLIDATED STATEMENT OF OPERATIONS (in millions, except per share data) Revenue $ 1,455.9 $ 1,377.6 $ 1,338.0 $ 2,833.5 $ 2,774.7 Cost of revenue (exclusive of amortization shown below) 900.9

More information

CMS ENERGY CORPORATION Earnings Per Share By Year GAAP Reconciliation (Unaudited)

CMS ENERGY CORPORATION Earnings Per Share By Year GAAP Reconciliation (Unaudited) GAAP Reconciliation CMS ENERGY CORPORATION Earnings Per Share By Year GAAP Reconciliation (Unaudited) 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Reported earnings (loss) per

More information

CSG SYSTEMS INTERNATIONAL, INC. DISCLOSURES FOR NON-GAAP FINANCIAL MEASURES

CSG SYSTEMS INTERNATIONAL, INC. DISCLOSURES FOR NON-GAAP FINANCIAL MEASURES CSG SYSTEMS INTERNATIONAL, INC. DISCLOSURES FOR NON-GAAP FINANCIAL MEASURES Use of Non-GAAP Financial Measures and Limitations To supplement its condensed consolidated financial statements presented in

More information

DELL TECHNOLOGIES INC.

DELL TECHNOLOGIES INC. Condensed Consolidated Statements of Income (Loss) and Related Financial Highlights (in millions, except per share amounts and percentages; unaudited) Net revenue: Products $ 12,968 $ 10,183 27 % Services

More information

Brooks Automation, Inc. 3 rd Quarter Fiscal 2013 Financial Results Conference Call

Brooks Automation, Inc. 3 rd Quarter Fiscal 2013 Financial Results Conference Call Brooks Automation, Inc. 3 rd Quarter Fiscal 2013 Financial Results Conference Call August 8, 2013 Safe Harbor Statement Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

CMS ENERGY CORPORATION Earnings Per Share By Year GAAP Reconciliation (Unaudited)

CMS ENERGY CORPORATION Earnings Per Share By Year GAAP Reconciliation (Unaudited) GAAP Reconciliation CMS ENERGY CORPORATION Earnings Per Share By Year GAAP Reconciliation (Unaudited) 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Reported earnings (loss) per

More information

Target Reports Fourth Quarter and Full-Year 2016 Earnings

Target Reports Fourth Quarter and Full-Year 2016 Earnings FOR IMMEDIATE RELEASE Contacts: John Hulbert, Investors, (612) 761-6627 Erin Conroy, Media, (612) 761-5928 Target Media Hotline, (612) 696-3400 Target Reports Fourth Quarter and Full-Year Earnings Fourth

More information

CMS ENERGY CORPORATION Earnings Per Share By Year GAAP Reconciliation (Unaudited)

CMS ENERGY CORPORATION Earnings Per Share By Year GAAP Reconciliation (Unaudited) GAAP Reconciliation CMS ENERGY CORPORATION Earnings Per Share By Year GAAP Reconciliation (Unaudited) 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Reported earnings (loss)

More information

October 26, Earnings Summary Third Quarter FY 2016

October 26, Earnings Summary Third Quarter FY 2016 October 26, 2016 Earnings Summary Third Quarter FY 2016 SAFE HARBOR Certain information contained in this presentation may constitute forward-looking statements within the meaning of the Private Securities

More information

Analog Devices, Third Quarter, Fiscal Schedule A Revenue and Earnings Summary (Unaudited) (In thousands, except per-share amounts)

Analog Devices, Third Quarter, Fiscal Schedule A Revenue and Earnings Summary (Unaudited) (In thousands, except per-share amounts) Analog Devices, Third Quarter, Fiscal Schedule A Revenue and Earnings Summary (Unaudited) (In thousands, except per-share amounts) Revenue $ 1,433,902 $ 1,147,982 $ 869,591 Year-to-year change 65% 47 %

More information

Q Supplemental Financial Information. February 1, 2018

Q Supplemental Financial Information. February 1, 2018 February 1, 2018 This presentation may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future

More information

FAIR ISAAC CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) (Unaudited)

FAIR ISAAC CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) (Unaudited) CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) March 31, September 30, 2016 2015 ASSETS: Current assets: Cash and cash equivalents $ 85,374 $ 86,120 Accounts receivable, net 155,207 158,773 Prepaid

More information

Fourth Quarter and Fiscal 2016 Results. 20 October 2016

Fourth Quarter and Fiscal 2016 Results. 20 October 2016 Fourth Quarter and Fiscal 2016 Results 20 October 2016 Safe harbor and non-gaap Cautionary Note Regarding Forward-Looking Statements: All statements in these materials and the related presentation that

More information

FAIR ISAAC CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) (Unaudited)

FAIR ISAAC CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) (Unaudited) CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) June 30, September 30, 2016 2015 ASSETS: Current assets: Cash and cash equivalents $ 118,155 $ 86,120 Accounts receivable, net 155,196 158,773 Prepaid

More information

2

2 News Release 1 2 3 4 5 6 Ashland Global Holdings Inc. and Consolidated Subsidiaries Table 1 STATEMENTS OF CONSOLIDATED INCOME (In millions except per share data - preliminary and unaudited) Three months

More information

SS&C Technologies Holdings, Inc. and Subsidiaries Condensed Consolidated Statements of Operations (in thousands, except per share data) (unaudited)

SS&C Technologies Holdings, Inc. and Subsidiaries Condensed Consolidated Statements of Operations (in thousands, except per share data) (unaudited) SS&C Technologies Holdings, Inc. and Subsidiaries Condensed Consolidated Statements of Operations (in thousands, except per share data) (unaudited) 2018 2017 Revenues: Software-enabled services $ 294,803

More information

Net sales $ 2,018 $ 1,965 Cost of sales 1,450 1,418 Gross profit

Net sales $ 2,018 $ 1,965 Cost of sales 1,450 1,418 Gross profit Condensed Consolidated Statements of Operations - Unaudited For the 2015 and 2014 (in millions, except per common share data) 2015 2014 Net sales $ 2,018 $ 1,965 Cost of sales 1,450 1,418 Gross profit

More information

Q1 16 Results. April 2016

Q1 16 Results. April 2016 Q1 16 Results April 2016 Safe harbor Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: This presentation and the accompanying conference call contain forward-looking statements

More information

Weighted Average Common and Common Equivalent Shares Outstanding 102, ,986

Weighted Average Common and Common Equivalent Shares Outstanding 102, ,986 SINCLAIR BROADCAST GROUP, INC. Reconciliation of Non-GAAP Measurements - Unaudited All periods reclassified to conform with current year GAAP presentation Quarters Ended Free Cash Flow (in thousands) 3/31/18

More information

SS&C Technologies Holdings, Inc. and Subsidiaries Condensed Consolidated Statements of Operations (in thousands, except per share data) (unaudited)

SS&C Technologies Holdings, Inc. and Subsidiaries Condensed Consolidated Statements of Operations (in thousands, except per share data) (unaudited) SS&C Technologies Holdings, Inc. and Subsidiaries Condensed Consolidated Statements of Operations (in thousands, except per share data) (unaudited) 2017 2016 2017 2016 Revenues: Software-enabled services

More information

CommScope Holding Company, Inc. Condensed Consolidated Statements of Operations (Unaudited -- In thousands, except per share amounts)

CommScope Holding Company, Inc. Condensed Consolidated Statements of Operations (Unaudited -- In thousands, except per share amounts) Condensed Consolidated Statements of Operations (Unaudited -- In thousands, except per share amounts) Three Months Ended March 31, 2018 2017 Net sales $ 1,120,517 $ 1,137,285 Operating costs and expenses:

More information